Overview
The Pharmacist’s Role in Individualizing Therapy for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Click the "Start Activity" button to indicate you have reviewed the CME/CE information for this activity.
Start Activity
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare, immune-mediated neurologic disorder that can lead to severe disability if left untreated. Early and accurate diagnosis for CIDP is challenging and usually delayed, but early initiation and maintenance of immunoglobulin-based treatment is crucial. Due to the heterogenous nature of the disease, treatment strategies need to be individualized, and pharmacists play an integral role through ongoing patient communications/education, treatment monitoring, dosing adjustments and switching between IVIg to subcutaneous Ig. To support pharmacists in this role, hear faculty offer insights on real-world CIDP cases including challenges with diagnosis and evidence-based treatment strategies for individualizing therapy.
This educational activity is intended for pharmacists involved in the management of patients with CIDP.
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare, immune-mediated neurologic disorder that can lead to severe disability if left untreated. Due to symptoms that overlap with other neurologic and neuropathic disorders, an early and accurate diagnosis for can be challenging and is usually delayed. However, prompt recognition is crucial for effective treatment. Due to the heterogenous nature of the disease, treatment strategies need to be individualized. First-line treatment with intravenous immunoglobulin (IVIg) has been shown to be efficacious for CIDP, but there is a substantial burden with long-term administration of these therapies. As subcutaneous immunoglobulin-based treatment options are increasingly available, pharmacists must be able to collaborate on selection of the right treatment, dose optimization, and switching strategies, if needed, for individual patients.
Upon completion of this activity, pharmacists will be able to:
• Discuss the latest safety and efficacy data surrounding novel immunoglobulin-based therapies for CIDP
• Employ timely and individualized treatment for patients with CIDP over the course of their illness
• Discuss the latest safety and efficacy data surrounding novel immunoglobulin-based therapies for CIDP
• Employ timely and individualized treatment for patients with CIDP over the course of their illness
Provided by the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
7. Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
• Case #1: 44 y/o noticed numbness and weakness in arms and legs over last 4 months. Patient is now experiencing gait difficulty.
• Case #2: 54 y/o reports numbness in arms and legs over past 6 months. Experiencing numbness, tingling, and hypersensitivity in hands, slight hand tremor, and problems with gait.
• Required testing to confirm a diagnosis of CIDP
• Potential pitfalls and red flags
• Variants of CIDP
• Disability associated with CIDP
• Treatment and management considerations: immunotherapy and new approaches
• Therapy selection
• IVIG vs SCIG for maintenance therapy and prevention of relapse
• Optimizing therapy
• Case #2: 54 y/o reports numbness in arms and legs over past 6 months. Experiencing numbness, tingling, and hypersensitivity in hands, slight hand tremor, and problems with gait.
• Required testing to confirm a diagnosis of CIDP
• Potential pitfalls and red flags
• Variants of CIDP
• Disability associated with CIDP
• Treatment and management considerations: immunotherapy and new approaches
• Therapy selection
• IVIG vs SCIG for maintenance therapy and prevention of relapse
• Optimizing therapy
Jeffrey Allen, MD
Professor, Department of Neurology
University of Minnesota
Minneapolis, MN
Professor, Department of Neurology
University of Minnesota
Minneapolis, MN
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with all ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
The following financial relationships have been provided:
Jeffrey Allen, MD
Advisory Board: Argenx, CSL Behring, Octapharma, Takeda
Consulting Agreements: Argenx, Grifols, ImmunoPharma, Immunovant, Sanofi, Takeda
Speakers Bureau: Alexion, Alnylam, Argenx, AstraZeneca, Takeda
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s).
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Discussion of scientific information on unapproved uses (SIUU), off-label, investigational, or experimental drug/device use: immunosuppressants, B cell-depleting agents, anti–tumor necrosis factor-α therapies
This activity will take approximately 60 minutes to complete. To receive credit, learners are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity has been approved for 1.0 contact hours.
ACPE Universal Activity Number: 0396-0000-24-023-H01-P
Activity Type: Application
Release Date: September 30, 2024
Expiration Date: September 30, 2025
CPE credit will be submitted to CPE Monitor® on the first business day of each month.
